natgillin/translations-raw huggingface dataset:
A compound of claim 1 or a racemic mixture, enantiomer, diastereomer, tautomer, or mixture thereof, or at least one pharmaceutically acceptable salt thereof; or a composition of claim 2 for use in treating a Syk- mediated disease, wherein the Syk- mediated disease is an inflammatory disease, an allergic disease, a cell- proliferative disease, an autoimmune disease or cytopenia. 
Spoj prema zahtjevu 1 ili njegova racemična smjesa, njegov enantiomer, dijastereomer, tautomer, ili njihova mješavina, ili najmanje jedna njegova farmaceutski prihvatljiva sol; ili sastav prema zahtjevu 2, naznačen/a time, da se upotrebljava u liječenju Syk-posredovane bolesti, pri čemu se kod Syk-posredovane bolesti radi o upalnoj bolesti, alergijskoj bolesti, bolesti stanične proliferacije, autoimunoj bolesti ili citopeniji.
Further, according to the embodiment described above, the abnormality specifying section 34e specifies that there is a scratch S2 on a reaction container 20 when the standard deviation of absorbance maintains a constant value while exceeding the threshold LT . 
Automatski analizator (1) prema zahtjevu 3, naznačen time da je dio za određivanje abnormalnosti (34e) konfiguriran da određuje da je reakcijska posuda (20) abnormalna kada mnoštvo standardnih devijacija prelazi prag (LT) i održava konstantnu vrijednost.
the first and second light chains comprise SEQ ID NO:8. 
(c) dva laka lanca od SEQ ID NO: 8.
(4-fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)methanamine hydrochloride Intermediate 63 was prepared according to procedure for intermediate 35. 
(4-fluoro-2-(3-metil-1H-1,2,4-triazol-1-il)fenil)metanamin hidroklorid: Intermedijer 63 je pripremljen prema postupku za Intermedijer 35.
The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 1, which is polymorph 1 and has at least reflections in an X-ray powder diffractogram using CuKa1 radiation at, 15.4, 16.8, 21.7 and 24.7 degrees 2theta ± 0.2 degrees 2theta. 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 1, naznačen time da je polimorf 1 i ima refleksije u difraktogramu X-zraka na prahu korištenjem CuKa, zračenja barem kod 4.5, 15.4, 16.8, 21.7 124.7 stupnjeva 2theta + 0.2 stupnjeva 2theta.
Possibilities of Application and Layer Arrangement 
Datum podnošenja zahtjeva u HR:
Package according to claim 6 or 7, characterized in that said one or more portions of fish in the solid form (10) have a soft consistence. 
Pakiranje sukladno zahtjevu 6 ili 7, naznačeno time što jedna 1li više porcija ribe u čvrstom obliku (10) imaju meku konzistenciju zbog upijanja otopine soli.
The compounds are described as having various uses, including as reagents useful in characterizing glutathione S-transferase (GST) isoenzymes, in determining the GST complements of cells and tissues, as chromatographic affinity ligands, binding agents, and enzyme inhibitors; and therapeutically to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exert cytotoxicity in tumor cells, elevate the production of granulocyte-macrophage (GM) progenitors in bone marrow, stimulate the differentiation of bone marrow, mitigate the bone marrow-destructive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Spojevi su opisani kao oni koji imaju različite upotrebe, uključujući i onu kao reagensi korisni u karakteriziranju glutation S-transferaze (GTS) izoenzima, u određivanju GST komplementarnih stanica 1 tkiva, kao ligandi kromatografskog afiniteta, agensi za vezivanje, i mhibitori enzima; i za terapiju: pojačavanje djelovanja citotoksika kemoterapijskih agensa u stanicama tumora, selektivno djelovanje citotoksiciteta u stanicama tumora, podizanje produkcije granulocit-makrofaga (GM) progenitora u koštanoj srži, stimuliranje diferencijacije koštane srži, ublažavanje destruktivnih efekata koštane srži zbog kemoterapijskih agenasa, i moduliranje hematopoiezisa u koštanoj srži.
weight percent of mannitol; 
masenih postotaka manitola;
The nails (50) are only on the shutters (11) of the opening side of the top of the lid (10). 
Ti čavlići se nalaze samo na zaklopcima (11) otvorene strane gornjeg dijela poklopca.
Example 8.2: Prediction of the Rf-genotype 
Datum objave europskog patenta:
oxidation of the carbon-carbon double bond of ring D of 3-A-oxy-17-C-oxy-estra-1,3,5(10),15-tetraene VI to form protected estetrol VII, wherein A and C are protecting groups; and 
(5) oksidacija dvostruke veze ugljik-ugljik prstena D 3-A-oksi-17-C-oksi-estra-1,3,5(10), 15-tetraena VI kako bi se dobio zaštitni estetrol VII, pri čemu su A 1 C zaštitne skupine; i
The system according to claim 1, wherein the second pressure is from 2 to 4 bars and is less than the first pressure. 
Sustav prema zahtjevu 1, naznačen time da je drugi tlak od 2 do 4 bara i manji je od prvog tlaka.
An isolated antibody according to paragraph 1 wherein the heavy chain comprises SEQ ID NO:21 and the light chain comprises SEQ ID NO:22. 
Izolirano protutijelo prema zahtjevu 1 naznačeno time da teški lanac sadrži SEQ ID NO:21 i lagani lanac sadrži SEQ ID NO:22.
analyzing previously delivered orders for food items to predict future orders for food items, and wherein the producing the plurality of food items is responsive to receipt of new orders for the food item and to predicted future orders for food items; and caching at least one unordered food item in an oven on the vehicle in anticipation of a new order for the food item. 
analiziranje prethodno dostavljenih narudžbi za prehrambene proizvode (104), kako bi se moglo predvidjeti buduće narudžbe za prehrambene proizvode, te time, da proizvodnja većeg broja prehrambenih proizvoda odgovara zaprimanju novih narudžbi za prehrambeni proizvod i predviđanju budućih narudžbi za prehrambene proizvode; i međupohranjivanje najmanje jednog nenaručenog prehrambenog proizvoda u štednjak (210) u vozilu (240), u iščekivanju nove narudžbe za prehrambeni proizvod.
A method of preparing a pharmaceutical composition, said method comprising admixing a GPR119 agonist and a DPP-IV inhibitor, together with at least one pharmaceutically acceptable carrier, wherein said DPP-IV inhibitor is not identical to 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728). 
Postupak priprave farmaceutskog pripravka, naznačen time, da navedeni postupak obuhvaća miješanje GPRI19 agonista i DPP-IV inhibitora skupa s barem jednom farmaceutski prihvatljivom podlogom, pri čemu navedeni DPP- IV inhibitor nije identičan s 1-[2-[(5-cijanopiridin-2-iljamino jetilamino |acetil-2-cijano-(S)-pirolidinom (NVP- DPP728).
The compound or salt of claim 48 wherein said disease is anorexia or cachexia resulting from or associated with cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu navedena kaheksija proizlazi iz ili je povezana s rakom.
A kit of claim 30 wherein any one or more of primers having of SEQ ID NOs. 
20, 22, 24 ili 29 zamijenjene mješavinom početnica sadržeći ili sastojeći se od sekvenci SEQ ID Nos.
The cement admixture as recited in claim 3, wherein said potentially hydraulic substance and/or said pozzolan substance contain one or two or more selected from the group consisting of finely pulverized, quenched, granulated blast-furnace slag, fly ash, silica fume, metakaolin, incinerated pulp sludge ash, incinerated sewage sludge ash, and waste glass powder. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što navedena potencijalno hidraulična tvar i/ili navedena pucolanska tvar sadrže jedan ili dva ili više od onoga što se bira iz skupine koju čine u fini prah mljevena gašena, granulirana troska iz visoke peći, leteći pepeo, koloidni silicijev dioksid, metakaolin, spaljeni pepeo mulja drvenjače, spaljeni pepeo kanalizacijskog mulja, te otpadni stakleni prah.
The apparatus according to claim 5, wherein a value of the active OFDM symbol duration field is one of 448 µs at 4k Fast Fourier Transformation, FFT, mode for 8 MHz bandwidth transmission system and 448 x (8/6) µs at 4k FFT mode for 6 MHz bandwidth transmission system. 
Uređaj prema zahtjevu 5, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k FFT, mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
The organic solution was then diluted with ethyl acetate (200mL) and concentrated by distillation at atmospheric pressure by distilling out 385mL of solvent. 
Organsku otopinu se zatim razrijedi etil-acetatom (200 ml), te koncentrira destilacijom pod atmosferskim tlakom, odestiliranjem 385 ml otapala.
The floating lake system of claim 1, wherein the bottom and/or walls of the floating lake are anchored to the bottom of the surrounding water body to cope with marine currents, winds, tides and specific weather conditions of the surrounding water body and environment. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što su dno (2) i/ili stjenke (3) plutajućeg jezera usidrene na dno (2) okolnog vodenog tijela kako bi se mogle nositi s morskim strujama, vjetrovima, plimom i osekom i specifičnim vremenskim uvjetima okolnog vodnog tijela i okoliša.
A method of preparing a composition according to claim 35, the method comprising admixing said inhibitor of dipeptidyl peptidase IV (DPP-IV) and said compound. 
Postupak izrade pripravka u skladu sa zahtjevom 35, naznačen time, da navedeni postupak obuhvaća miješanje navedenog inhibitora dipeptidil peptidaze IV (DPP-IV) i navedenog spoja.
providing an aqueous emulsion phase comprising water and a surfactant, and human interferon alpha-2b and 0.01 to 0.5 weight percent of L-methionine incorporated in the emulsion, wherein the aqueous phase further comprises an additional antioxidant, a chelating agent, and/or a protein stabilizer; and 
(a) - pripremu faze vodene emulzije koja sadržava vodu i površinski djelatno sredstvo te humani interferon alfa-2b i 0,01 do 0,5 težinskog udjela L-metionina uključenog u emulziju, pri čemu vodena faza nadalje sadržava dodatni antioksidans, sredstva za tvorbu kelata i/ili stabilizatore proteina; i
An in vitro method of inducing an antigen-presenting cell having a high cytotoxic T cell inducibility comprising the step of: 
Postupak induciranja stanice za predočavanje antigena koja može inducirati citotoksičnu T-stanicu in vitro, naznačen time što se sastoji u koraku:
An antibody which binds membrane-bound human carcinoembryonic antigen (CEA), wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 239 and SEQ ID NO: 247 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 209. 
Protutijelo, naznačeno time, da ono veže membranski vezani humani karcinoembrionski antigen (CEA), pri čemu varijabilna regija teškog lanca sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 239 1 SEQ ID NO: 247, te pritom varijabilna regija lakog lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 209.
The use according to claim 1, wherein the substance is nicotine. 
Uporaba prema zahtjevu 7, naznačena time da poremećaj je shizofrenija.
The compound 3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, according to claim 1 for use in the treatment of chronic obstructive pulmonary disease. 
Spoj, naznačen time, da je to 3-amino-6-(4-fluoro-fenil)-5-trifluorometil-piridin-2-karboksilna kiselina-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, te time, da se on upotrebljava za liječenje kronične opstrukcijske plućne bolesti.
treating the mesopoxphyrin IX dihydrochloride with diatomaceous earth and activated carbon, then adding 0.1 to 6N HCl to the mesoporphyrin IX dichloride; 
obradom Mezoporfirin IX-dihidroklorida diatomejskom zemljom i aktiviranim ugljikom, te dodavanjem 0,1 N do 6 N HCl Mezoporfirin IX-dihidrokloridu
reacting said racemate with any of the enantiomers of an optically active acetylated amino acid of formula (III): wherein n and R1 are as defined above; 
(dB) gdje je HX optički aktivna acetilirana aminokiselina formule (III): gdje: nje0,1,2ili3,
the first compound corresponds in structure to Formula (I-d) or a pharmaceutically acceptable salt thereof; and 
(ib) ili njegovu farmaceutski prihvatljivu sol; i drugi spoj čija struktura odgovara Formuli (II-b):
a2c Adrenergic receptor binding activity was determined using the method of Uhlen et al., J. Pharmacol. 
Aktivnost vezivanja o2C adrenergičkog receptora je bila određena uporabom postupka po Uhlen i sur., J. Pharmacol.
The process according any one of claims 5 or 6, characterized in that the precipitated calcium carbonate is ultrafine discrete prismatic, scalenohedral or rhombohedral precipitated calcium carbonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 5 ili 6, naznačen time što je istaloženi kalcijev karbonat ultrafini diskretni prizmatični, skalenoedarski ili romboedarski istaloženi kalcijev karbonat.
The vaccine composition of claim 2, wherein said acrylic polymer is an alkyl-polyacrylic acid ("alkyl-PAA") adjuvant. 
Cjepivni pripravak u skladu s patentnim zahtjevom 2, naznačen time što je navedeni akrilni polimer alkil- poliakrilna kiselina ("alkil-PAA") kao adjuvans.
A vaccine comprising the vaccine component of claim 13. 
Cjepivo koje sadrži komponentu cjepiva prema zahtjevu 13.
The filtrate was evaporated and the residue was dissolved in methylene chloride (2000 ml) and the solution was washed with water (2000 ml). 
Filtrat se ispari i ostatak se otopi u metilen kloridu (2000 ml) i otopina se pere vodom (2000 ml).
The suspension was allowed to settle for 15 hours for the larger particles to separate out. 
Suspenzija je ostavljena da se istaloži 15 sati i velike čestice su izdvojene.
A compound of formula (Ia), or stereoisomers or pharmaceutically acceptable salts thereof, wherein 
Spoj formule (Ia) ili njegovih stereoizomera ili farmaceutski prihvatljivih soli, [image] naznačen time, da
is selected from hydrogen or F; 
R? je izabran od vodika ili F;
The pharmaceutical composition of claim 1, comprising droxidopa in combination with donepezil. 
Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama s donepezilom.
It is also believed that administration of Compound I in combination with one or more antidiabetic compounds to type I or type II diabetic patients following a minimum treatment of at least 30 days will improve one or more cardiovascular measurements. 
Upotreba farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38 u kombinaciji sa jednim ili više antidijabetičnih spojeva koji se razlikuju od spoja I za proizvodnju lijeka za liječenje dijabetesa tipa II, pri čemu spoj I ima formulu 44.
The hydrophobic core has a major impact on the uniqueness and stability of the Ig fold. 
Hidrofobna jezgra ima snažan utjecaj na jedinstvenost i stabilnost Ig-smota.
Then diluted with EtOAc (200 mL), washed with water (2×50 mL), brine (50 mL), dried (Na2SO4), filtered and concentrated to give viscous yellow oil. 
Zatim je razrijeđena sa EtOAc (200 mL), isprana vodom (2 X 50 mL), slanom otopinom (50 mL), sušena (Na,SOx), filtrirana i koncentrirana da bi se dobilo viskozno žuto ulje.
A compound according to Claim 6 for use in the treatment of a disease selected from of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune diseases, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, autoimmune diseases, systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity. 
Spoj prema Zahtjevu 6 za uporabu u liječenju bolesti izabrane između reumatoidnog artritisa, ankilozantnog spondilitisa, osteoartritisa, psorijatičnog artritisa, psorijaze, upalnih bolesti i autoimunih bolesti, upalnih poremećaja crijeva, upalnih poremećaja oka, upalnih poremećaja mjehura ili poremećaja nestabilnog mjehura, kožnih tegoba s upalnim komponentama, kroničnih upalnih stanja, autoimunih bolesti, sistemskog eritematoznog lupusa (SLE), miastenije gravis, reumatoidnog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosjetljivosti.
Use of nanoparticles or nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide selected from the group consisting of CeO2, Tm2O3, HfO2, WO3 and PdO, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7,1 g/cm3 when the metal oxide is CeO2, of at least 8,3 g/cm3 when the metal oxide is Tm2O3, of at least 7,4 g/cm3 when the metal oxide is HfO2, of at least 7,2 g/cm3 when the metal oxide is WO3, and of at least 7,9 g/cm3 when the metal oxide is PdO, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Uporaba nanočestica HfO2 ili agregata nanočestica HfO2 za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO2 ili gustoća spomenutih agregata nanočestica HfO2 barem 7 g/cm3, i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 i 7,5 u fiziološkoj tekućini.
Number of Administration Blank Control 
Broj međunarodne objave:
A nucleic acid encoding a protein according to any one of claims 1-8. 
Nukleinska kiselina koja kodira varijantu proteina prema patentnom zahtjevu 1.
In accordance with claim 2, the method further includes the step of transporting the isolated polypropiolactone to the second location prior to pyrolyzing at least some of the isolated polypropiolactone to liberate acrylic acid. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje korak transporta izdvojenog polipropiolaktona na drugu lokaciju prije navedenog piroliziranja, gdje se po mogućnosti korak transporta sastoji u seljenju polipropiolaktona na udaljenosti većoj od 100 milja (160 km).
represents a halogen atom or an alkyl group; the alkyl group may be substituted by a hydroxyl group; 
predstavlja atom halogena ili alkilnu skupinu; alkilna skupina može biti supstituirana s hidroksilnom skupinom;
The method of claim 7, wherein isolating (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol (2) in step b) comprises adding water and adjusting the pH of the aqueous phase to about 2 by addition of an acidic solution. 
Postupak prema zahtjevu 7, naznačen time da izoliranje (52,87,117,147,177)-ikoza-5,8,11,14,17-pentaen-1-ola (2) u koraku b) sadrži dodavanje vode i podešavanje pH vodene faze do oko 2 dodavanjem kisele otopine. 9.
an internal support (1960), the internal support capable of telescoping from a collapsed position to an extended position; 
unutarnji nosač (1960) koji se može izdići iz spuštenog u produljeni položaj;
a binding domain capable of binding to the three fibronectin type III domains having seq ID:444 and the L2 domain having seq ID:445 of the extracellular domain of IGF-1R. 
(e) vežuća domena, koja se može vezati na tri fibronektin tip III domene sa SEQ ID:444 i L2 domenu sa SEQ 1D:445 izvanstanične domene IGF-IR.
A composition for use according to claim 1-3 wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
Pripravak za uporabu prema zahtjevu 1-3, naznačen time da je doza slobodne baze dezmopresina u obliku acetatne soli dezmopresina.
FIG. 14 . 48-hour TG peritonitis model in hCCR2 KI mice: Example 1 inhibition of monocyte/macrophage infiltration into peritoneal cavity (differential cell count). 
SLIKA 14 48-satni tioglikolatni (TG) model peritonitisa u hCCR2 K1 miševa: Primjer 1 inhibicija infiltracije monocita/makrofaga u peritonealnu šupljinu (diferencijalni broj stanica)
the cfDNA sample is from a blood sample obtained within seven days of transplant; 
(iv) uzorak cfDNK je dobiven iz uzorka krvi uzetog unutar sedam dana od presađivanja;
In the present situation, the cutting/slicing plane is selected perpendicular to the plane which is defined by the adhesion layers 20, and, actually, in longitudinal direction of the block of wood, so that regular veneers resulted having a width of 600 mm and a length of 2,400 mm. 
U predmetnom slučaju ravnina rezanja/rezanja na kriške je odabrana okomito na ravninu koja je definirana slojem ljepila 20, i, u stvarnosti, u uzdužnom smjeru bloka od drva, tako da su nastali uobičajeni furniri koji su imali širinu od 600 mm i dužinu od 2,400 mm.
The method according to claim 3, wherein said at least one other anti-cancer agent is selected from the group of: trastuzumab, capecitabine, paclitaxel, carboplatin, pazopanib and letrozole. 
Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju ljudi od raka prema zahtjevu 3, naznačen/a time, da se najmanje jedno neko drugo sredstvo protiv raka odabire iz skupine od sljedećih: trastuzumab, kapecitabin, paklitaksel, karboplatin, pazopanib i letrozol.
The drippable ophthalmic gel according to claim 1 characterized in that the amount of polyacrylate is in the range of >0.2% to 3.0% by weight. 
Bimatoprost oftalmološki gel u obliku kapi temeljem zahtjeva 1, naznačen time da je količina poliakrilata u rasponu od > 0,2 % do 3,0 % masenog udjela, poželjno u rasponu od > 0,2 % do 0,7 % masenog udjela.
reacting crude Compound 8 with a metal bisulfite to produce Compound 9: 
reakciju sirovog spoja 8 sa metal bisulfitom da se proizvede spoj 9: [image]
a transfer vehicle, a pharmaceutically acceptable excipient, and at least one mRNA molecule encoding a protein, the transfer vehicle comprising one or more cationic lipid(s), one or more non-cationic lipid(s), and one or more PEG- modified lipid(s), wherein the transfer vehicle is a liposome and the size of the transfer vehicle is less than 100 nm. 
nosač transfera, farmaceutski prihvatljiv ekscipijent i najmanje jednu iRNK molekulu koja kodira protein, nosač transfera koji sadrži jedan ili više kationskih lipida, jedan ili više nekationskih lipida i jedan ili više lipida modificiranih s PEG, pri čemu je nosač transfera liposom, a veličina nosača transfera je manja od 100 nm.
The base elastomer was taken and its absorption coefficient a was measured. 
Bio je uzet osnovni elastomer i bio je izmjeren njegov koeficijent apsorpcije a.
wherein copanlisib, of formula (7): is allowed to react with hydrogen chloride, optionally hydrochloric acid, thereby providing copanlisib dihydrochloride (8): 
O D, ostavljen da reagira s hidrogen kloridom, čime se dobiva kopanlisib dihidroklorid (8):
From these tests, it was concluded that - for both the crumb color and mouthfeel - those cakes prepared with the sugar replacement composition according to the invention, scored significantly better than the sugar containing cakes. 
Obavljena je analiza pokazala da su boja unutrašnjosti 1 tekstura kolača pripravljenih prema ovom izumu sa sastavinom koja zamjenjuje šećer dobile značajno bolju ocjenu od kolača pripravljenih sa šećerom.
An inhalable pharmaceutical solution aerosol for use as claimed in claim 1, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.8-1.2 µm. 
Farmaceutska otopina aerosola za inhalaciju u skladu s patentnim zahtjevom 1, pri čemu aerosol ima veličinu kapljica koje imaju medijan aerodinamičkog promjera mase od 0.8 - 1.2 um.